From Automation to Decision Intelligence: The Next Operating Model for Pharmacovigilance
Everyone agrees that AI is changing pharmacovigilance. But the nature of that change is evolving. The first wave of AI deployment in pharmacovigilance focused on automating repetitive tasks, but the technology is ready for more than that now: it can help free up experts to focus on the complex decisions that matter most for patients.
In this free white paper, IQVIA experts and thought leaders explore the real challenges and bottlenecks in pharmacovigilance today, including the unprecedented volume of data and shortage of personnel interested in the space. We describe how AI can help address these challenges and how companies can overcome challenges of trust and veracity, decision velocity, and organisational readiness.
What you’ll learn from this white paper:
- What AI is capable of in pharmacovigilance
- Why the human in the loop is still important, and how to maximise their value
- Friction points in enterprise AI deployment and how to respond to them
- What the future might have in store for pharmacovigilance AI
The world of pharmacovigilance is changing fast – don’t get left behind.
Download the full white paper now and discover how AI is transforming the landscape.
About IQVIA Technologies
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions and Healthcare-grade AI® are powered by IQVIA Connected Intelligence™ to deliver actionable insights and accelerate innovations. With approximately 93,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. Learn more at www.iqvia.com
